New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
12.07
1.15
−8.70%
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 51 | — | 12 | 6 | 7 | (48.5%) | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | 100.00 | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | 51 | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | 100.00 | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | 21.07 | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | (8.98) | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | 2 | — | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | n/m | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 1.84 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.36 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | — | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | — | — | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026
Scribe Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics, Inc. | $262.2M | — (loss-making) | 19.9× FY25e | — | n/m | −9.96% (below 0%: shrinking) | 100.00% | (8,726.07%) | Compare |
| AUTL Autolus Therapeutics PLC Sponsored ADR | $260.9M | — (loss-making) | — (loss-making) | +94.57% (above 0%: growing) | n/m | +75.40% (above 0%: growing) | 56.53% | (105.57%) | Compare |
| PRLD Prelude Therapeutics Incorporated | $260.5M | — (loss-making) | — (loss-making) | −13.12% (below 0%: shrinking) | n/m | +27.92% (above 0%: growing) | 100.00% | (252.61%) | Compare |
| EIKN Eikon Therapeutics, Inc. | $257.9M | — (loss-making) | — | — | n/m | −12.03% (below 0%: shrinking) | — | — | Compare |
| QTTB Q32 Bio Inc. | $253.8M | 2.5× | — (loss-making) | −1,928.18% (below 0%: shrinking) | n/m | −4.44% (below 0%: shrinking) | 100.00% | 176.03% | Compare |
| CAMP CAMP4 Therapeutics Corporation | $251.0M | — (loss-making) | — (loss-making) | +138.87% (above 0%: growing) | n/m | +20.36% (above 0%: growing) | 100.00% | (738.76%) | Compare |
| SCTX Scribe Therapeutics Inc. | $250.4M | — (loss-making) | — (loss-making) | — | n/m | — | 100.00% | (663.94%) | |
| OCGN Ocugen, Inc. | $248.6M | — (loss-making) | — (loss-making) | +11.36% (above 0%: growing) | n/m | −22.15% (below 0%: shrinking) | 100.00% | (909.94%) | Compare |
| IPSC Century Therapeutics, Inc. | $239.7M | — (loss-making) | — (loss-making) | +12,667.72% (above 0%: growing) | n/m | +11.70% (above 0%: growing) | 100.00% | 67.95% | Compare |
| Median of peers | $255.8M | — | — | +52.97% | — | +3.63% | 100.00% | (252.61%) |
Scribe Therapeutics Inc. (SCTX) Latest News
What happened
- Product Scribe Therapeutics reported that STX-1150 lowered LDL-C by more than 50% for two years in non-human primates and STX-1200 reduced Lp(a) by more than 95%.
- Deal Scribe Therapeutics expanded its collaboration with Sanofi to include its ELXR epigenetic silencing platform for early-stage research.
- Results Scribe Therapeutics reported a third-quarter net loss of $9.9 million and $174.2 million in cash and marketable securities at quarter-end.
- Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought The Motley Fool
- Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- Scribe’s Genetic Editing Aims to Prevent Heart Attacks
- Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
- Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
- Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering